Corporate GovernanceJul 17, 2026, 05:06 PM
Karyopharm Implements $3.71M Leadership Cash Retention Program
AI Summary
Karyopharm Therapeutics Inc. has implemented a 2026 Leadership Cash Retention Program totaling $3.71 million for certain key employees, including its named executive officers and Chief Financial Officer. The program aims to incentivize retention during a period of anticipated meaningful catalysts for the company. These cash retention awards replace previously guaranteed amounts under the 2026 Annual Bonus Plan and are subject to repayment conditions if employment is terminated prematurely.
Key Highlights
- Total cash retention awards amount to $3,710,000 for key executives.
- Richard Paulson, CEO, to receive $1,725,000.
- Stuart Poulton, Chief Development Officer, to receive $640,000.
- Dr. Reshma Rangwala, Chief Medical Officer, to receive $725,000.
- Lori Macomber, CFO, to receive $625,000.
- Awards are subject to repayment if employment terminates under certain conditions within 12 months or 30 days post-corporate event.
Price Impact
More from KPTI
Corporate GovernanceMay 28, 4:21 PM
Karyopharm Stockholders Approve 3M Share Equity Plan Increase; Grants PSUs
Quarterly ResultMay 14, 7:52 AM
Karyopharm Raises Going Concern Doubt; Q1 Net Loss $(22.4)M
Quarterly ResultMay 14, 7:37 AM
Karyopharm Q1 Total Revenue $35.1M; Endometrial Cancer Trial Enrollment Complete